Utah Medical Products, Inc.
NASDAQ:UTMDMedical - Instruments & Supplies
+$1.10 today
- Market cap
- $205.81M
- Beta
- 0.37
- P/E (TTM)
- 19.6
- EPS (TTM)
- $3.41
- Dividend yield
- 1.85%
Volume 0.02M
Average 0.01M
UTMD Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Utah Medical Products, Inc.NASDAQ: UTMD
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures dips below year-ago levels
Q1 FY2026 capital expenditures of $130K (cash outflow) fell 29.3% year over year, behind the +85.4% change in trailing-twelve-month capital expenditures. Sequentially, it rose 19.3% from the prior quarter. Over 3 fiscal years it compounded at -23.2% a year.
Context
- Capital expenditures amounted to 1.0% of revenue in FY2025, up 0.4 pp from a year earlier.
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -29.3% toward the trailing-twelve-month pace of +85.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (371K) USD
- Year-over-year change
- -57.9%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (371K) | -57.9% |
| FY2024 | 2024-12-31 | (235K) | +63.2% |
| FY2023 | 2023-12-31 | (639K) | +21.9% |
| FY2022 | 2022-12-31 | (818K) | -48.2% |
| FY2021 | 2021-12-31 | (552K) | — |
Capital Expenditures vs competitors
How UTMD compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +85.4% is the highest of 8, against a peer median of -63.3%.
- Capital expenditures amounts to 0.8% of revenue for UTMD, versus a peer median of 1.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $14.95M USD | -70.1% | +248.2% | 2419.3% | |
| LTM Mar 2026 | $4.69M USD | +77.8% | -96.0% | 4.1% | |
| LTM Mar 2026 | $3.3M USD | -63.3% | -66.6% | 2.3% | |
| LTM Mar 2026 | €1.32M EUR | -65.8% | -63.4% | 8.1% | |
| LTM Mar 2026 | $779K USD | -40.5% | -37.4% | 0.5% | |
| LTM Mar 2026 | $578.97K USD | -64.0% | -30.7% | 1.3% | |
| LTM Mar 2026 | $455K USD | -54.0% | +37.7% | 0.6% | |
| LTM Mar 2026 | $317K USD | +85.4% | -23.2% | 0.8% | |
| LTM Mar 2026 | $208K USD | — | -68.0% | 0.2% | |
| LTM Mar 2026 | $179.08K USD | — | — | 0.9% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding UTMD) | — | -63.3% | -50.4% | 1.1% | |
Competitors are the stored peer set for UTMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 14.79M | 16.47M | 16.64M | 13.87M | 11.29M |
| Depreciation & Amortization | 7.28M | 7.08M | 6.37M | 2.85M | 3.01M |
| Deferred Income Tax | (92K) | (401K) | (681K) | (338K) | (659K) |
| Stock-Based Compensation | 166K | 183K | 225K | 256K | 373K |
| Change in Working Capital | (1.01M) | (2.23M) | (233K) | (1.8M) | 317K |
| Accounts Receivables | (1.13M) | (525K) | 2.27M | (781K) | 333K |
| Inventory | (485K) | (2.35M) | (670K) | 587K | 1.2M |
| Accounts Payables | (23K) | 464K | (456K) | (73K) | 211K |
| Other Working Capital | 632K | 188K | (1.38M) | (1.54M) | (1.42M) |
| Other Non-Cash Items | 63K | 36K | (33K) | (4K) | 367K |
| Operating Cash Flow | 21.2M | 21.15M | 22.28M | 14.83M | 14.69M |
| Capital Expenditures | (552K) | (818K) | (639K) | (235K) | (371K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (9K) | 0 | 27K | 0 |
| Investing Cash Flow | (552K) | (818K) | (639K) | (208K) | (371K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | (2.5M) | 0 | (19.97M) | (8.36M) |
| Dividends Paid | (11.47M) | (3.16M) | (4.28M) | (4.26M) | (3.98M) |
| Other Financing Activities | 560K | 174K | 117K | 390K | 0 |
| Financing Cash Flow | (10.91M) | (5.48M) | (4.17M) | (23.84M) | (12.34M) |
| Effect of Forex Changes | (362K) | (767K) | 339K | (677K) | 797K |
| Net Change in Cash | 9.38M | 14.08M | 17.82M | (9.89M) | 2.78M |
| Free Cash Flow | 20.65M | 20.33M | 21.64M | 14.6M | 14.32M |
Utah Medical Products, Inc.
NASDAQ:UTMD
Intrinsic Alpha fair value
Locked
Current Price
$72.24
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.